Results of a phase II clinical trial to evaluate a re-challenge of intraperitoneal catumaxomab for treatment of malignant ascites (MA) due to epithelial cancer (SECIMAS).
Klaus Pietzner
No relevant relationships to disclose
Ignace Vergote
No relevant relationships to disclose
Armando Santoro
No relevant relationships to disclose
Frederik Marme
No relevant relationships to disclose
Per Rosenberg
No relevant relationships to disclose
Hilke Friccius-Quecke
Employment or Leadership Position - Fresenius Biotech
Jalid Sehouli
No relevant relationships to disclose